DEF 14A: Eterna Therapeutics Seeks Stockholder Approval for Key Proposals at Upcoming Annual Meeting

Eterna Therapeutics is asking stockholders to vote on the election of directors, ratification of auditors, and a stock issuance proposal at its annual meeting on October 29, 2024.

Summary

• Eterna Therapeutics Inc. is holding its 2024 annual meeting of stockholders on October 29, 2024, to vote on several key proposals.
• The proposals include electing five nominees to the board of directors, ratifying the appointment of Grant Thornton LLP as the company's independent registered public accounting firm for the 2024 fiscal year, and approving a stock issuance proposal to comply with Nasdaq listing rules.
• The stock issuance proposal involves the issuance of common stock pursuant to a securities purchase agreement dated September 24, 2024, in exchange for outstanding convertible notes and warrants, and upon conversion of 12% senior convertible notes.
• The board of directors recommends voting FOR all the proposed resolutions.
• The meeting will be a virtual meeting conducted via live audio webcast.
• Stockholders of record as of October 1, 2024, are entitled to vote.
• As of the record date, there were 5,410,588 shares of common stock issued and outstanding.
• The company entered into support agreements on September 25, 2024, with stockholders who owned approximately 48% of the outstanding shares of common stock as of the record date.
• The company is seeking approval to issue approximately 47.8 million shares of common stock under the SPA and the Exchange Agreements and upon conversion of the bridge notes.

Sentiment

Score: 4

Explanation: The document contains both positive and negative elements. The proposed stock issuance and debt restructuring could improve the company's financial position, but there are also risks associated with dilution and potential delisting from Nasdaq.

Positives

• The proposed stock issuance aims to strengthen the company's financial position and comply with Nasdaq listing rules.
• The board of directors is actively engaged in corporate governance and risk oversight.
• The company has adopted a clawback policy for incentive-based compensation.
• The company is terminating a sublease which is expected to save approximately $58.5 million in base rental payments plus parking, operating expenses, taxes and utilities that we would have paid over the remaining lease term.

Negatives

• The company has a history of related party transactions.
• The company has received a notice from Nasdaq stating that the Staff has determined that we did not meet the terms of the extension to confirm or demonstrate compliance with the Minimum Stockholders Equity Rule by September 16, 2024.
• The issuance of the Transaction Shares will substantially dilute the ownership percentage of our outstanding common stock by our stockholders and their percentage interest in the voting power, liquidation value and book value of our common stock.
• The conversion rate of our Series A convertible preferred stock is expected to decrease from 8.3038 per share to 5.0728 per share.
• If the warrants are exchanged for shares of common stock under the Exchange Agreement, we will forego such potential proceeds of approximately $28.5 million.
• The issuance of the Transaction Shares could affect trading patterns and adversely affect the market price of our common stock.
• The issuance of the Transaction Shares, alone or in combination with past issuances and transfers of shares of our common stock, may result in an ownership change within the meaning of Section 382, which would limit our ability to use our pre-ownership change NOLs and other tax attributes.

Risks

• Failure to obtain stockholder approval for the stock issuance proposal could lead to delisting from Nasdaq.
• The company's ability to use net operating loss carryforwards may be limited due to potential ownership changes.
• The company's largest stockholder, Charles Cherington, will have significant influence over the company after the issuance of the Transaction Shares.
• The company may not be able to demonstrate compliance with the Minimum Stockholders Equity Rule and avoid a delisting of our common stock.

Future Outlook

The company is focused on regaining compliance with Nasdaq listing rules and executing its business plan.

Industry Context

The company operates in the biotechnology industry, which is characterized by high risk and uncertainty.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• Without specific financial benchmarks or performance metrics relative to comparable companies, a comprehensive assessment is not possible.
• Comparable companies in the biotechnology industry include Deciphera Pharmaceuticals and Erasca, Inc., where James Bristol serves as a board member.

Management Changes

Corporate Governance

Related Party Transactions

• The company has or had agreements with Factor Bioscience Inc. and/or Dr. Matthew Angel.
• The Exacis Acquisition was deemed a related party transaction.
• Investors in the July 2023 and December 2023 convertible note financings included former directors.
• The company entered into a securities purchase agreement with certain investors in November 2022, including former directors.

Stakeholder Impact

• Stockholders will be impacted by the potential dilution from the stock issuance.
• Employees may be impacted by the company's efforts to regain compliance with Nasdaq listing rules.
• Creditors may be impacted by the restructuring of the company's debt.
• The company is terminating a sublease which is expected to save approximately $58.5 million in base rental payments plus parking, operating expenses, taxes and utilities that we would have paid over the remaining lease term.

Next Steps

• Stockholder vote on the proposed resolutions at the annual meeting on October 29, 2024.
• Closing of the transactions contemplated by the SPA and Exchange Agreements, subject to stockholder approval and other conditions.
• Hearing with the Nasdaqs Hearings Panel to appeal the Staffs determination on November 12, 2024.
• Efforts to regain compliance with Nasdaq listing rules.

Key Dates

Keywords

stockholders, directors, issuance, Nasdaq, Eterna, Therapeutics, meeting, common stock, convertible notes, warrants